These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 11447320)

  • 1. Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease.
    Lastres-Becker I; Fezza F; Cebeira M; Bisogno T; Ramos JA; Milone A; Fernández-Ruiz J; Di Marzo V
    Neuroreport; 2001 Jul; 12(10):2125-9. PubMed ID: 11447320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.
    Lastres-Becker I; Hansen HH; Berrendero F; De Miguel R; Pérez-Rosado A; Manzanares J; Ramos JA; Fernández-Ruiz J
    Synapse; 2002 Apr; 44(1):23-35. PubMed ID: 11842443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease.
    Lastres-Becker I; de Miguel R; De Petrocellis L; Makriyannis A; Di Marzo V; Fernández-Ruiz J
    J Neurochem; 2003 Mar; 84(5):1097-109. PubMed ID: 12603833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
    Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
    Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease.
    Lastres-Becker I; Berrendero F; Lucas JJ; Martín-Aparicio E; Yamamoto A; Ramos JA; Fernández-Ruiz JJ
    Brain Res; 2002 Mar; 929(2):236-42. PubMed ID: 11864629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.
    Cabranes A; Venderova K; de Lago E; Fezza F; Sánchez A; Mestre L; Valenti M; García-Merino A; Ramos JA; Di Marzo V; Fernández-Ruiz J
    Neurobiol Dis; 2005 Nov; 20(2):207-17. PubMed ID: 16242629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.
    de Lago E; Fernández-Ruiz J; Ortega-Gutiérrez S; Cabranes A; Pryce G; Baker D; López-Rodríguez M; Ramos JA
    Eur Neuropsychopharmacol; 2006 Jan; 16(1):7-18. PubMed ID: 16006105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of cannabinoid CB(1) receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington's disease.
    Lastres-Becker I; Gómez M; De Miguel R; Ramos JA; Fernández-Ruiz J
    Neurotox Res; 2002; 4(7-8):601-608. PubMed ID: 12709298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease.
    Glass M; Dragunow M; Faull RL
    Neuroscience; 2000; 97(3):505-19. PubMed ID: 10828533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease.
    Di Marzo V; Hill MP; Bisogno T; Crossman AR; Brotchie JM
    FASEB J; 2000 Jul; 14(10):1432-8. PubMed ID: 10877836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease.
    de Lago E; Urbani P; Ramos JA; Di Marzo V; Fernández-Ruiz J
    Brain Res; 2005 Jul; 1050(1-2):210-6. PubMed ID: 15975564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of systemic 3-nitropropionic acid-induced lesions of the dorsal striatum on cannabinoid and mu-opioid receptor binding in the basal ganglia.
    Page KJ; Besret L; Jain M; Monaghan EM; Dunnett SB; Everitt BJ
    Exp Brain Res; 2000 Jan; 130(2):142-50. PubMed ID: 10672467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protopanaxtriol protects against 3-nitropropionic acid-induced oxidative stress in a rat model of Huntington's disease.
    Gao Y; Chu SF; Li JP; Zhang Z; Yan JQ; Wen ZL; Xia CY; Mou Z; Wang ZZ; He WB; Guo XF; Wei GN; Chen NH
    Acta Pharmacol Sin; 2015 Mar; 36(3):311-22. PubMed ID: 25640478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission.
    Gubellini P; Picconi B; Bari M; Battista N; Calabresi P; Centonze D; Bernardi G; Finazzi-Agrò A; Maccarrone M
    J Neurosci; 2002 Aug; 22(16):6900-7. PubMed ID: 12177188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocannabinoid-Specific Impairment in Synaptic Plasticity in Striatum of Huntington's Disease Mouse Model.
    Sepers MD; Smith-Dijak A; LeDue J; Kolodziejczyk K; Mackie K; Raymond LA
    J Neurosci; 2018 Jan; 38(3):544-554. PubMed ID: 29192125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease.
    Allen KL; Waldvogel HJ; Glass M; Faull RL
    J Chem Neuroanat; 2009 Jul; 37(4):266-81. PubMed ID: 19481011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of intrastriatal injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington's disease.
    Shear DA; Dong J; Gundy CD; Haik-Creguer KL; Dunbar GL
    Prog Neuropsychopharmacol Biol Psychiatry; 1998 Oct; 22(7):1217-40. PubMed ID: 9829299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease.
    González S; Scorticati C; García-Arencibia M; de Miguel R; Ramos JA; Fernández-Ruiz J
    Brain Res; 2006 Feb; 1073-1074():209-19. PubMed ID: 16412990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The endocannabinoid system in Huntington's disease.
    Pazos MR; Sagredo O; Fernández-Ruiz J
    Curr Pharm Des; 2008; 14(23):2317-25. PubMed ID: 18781982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The endogenous cannabinoid system and the basal ganglia. biochemical, pharmacological, and therapeutic aspects.
    Romero J; Lastres-Becker I; de Miguel R; Berrendero F; Ramos JA; Fernández-Ruiz J
    Pharmacol Ther; 2002 Aug; 95(2):137-52. PubMed ID: 12182961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.